Industry & Policy News

[Weill Cornell Medicine] PICI announced it has added Weill Cornell Medicine to its network of preeminent academic and medical research institutions at the forefront of the fight against cancer.

89bio, Inc. announced a successful end-of-phase II Meeting with the US FDA, supporting the advancement of pegozafermin into Phase III in NASH. The program will include two Phase 3 trials evaluating...

[The University of Toronto] The University of Toronto’s Medicine by Design initiative and CCRM, a non-profit that supports the development and commercialization of regenerative medicines, are launching a new strategic alliance that aims to unlock Toronto’s potential as a world-leading ecosystem for regenerative medicine.

[Icosavax, Inc.] Icosavax, Inc. announced positive topline interim results from its Phase II clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.

[US FDA] The US FDA approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years and older.

[Bristol-Myers Squibb K.K.] Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma®, a B cell maturation antigen-directed CAR T cell immunotherapy.